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Abstract: Melatonin is an endogenous indoleamine present in different tissues, cellular compartments and organelles  
including mitochondria. When melatonin is administered orally, it is readily available to the brain where it counteracts  
different processes that occur during aging and age-related neurodegenerative disorders. These aging processes include 
oxidative stress and oxidative damage, chronic and acute inflammation, mitochondrial dysfunction and loss of neural  
regeneration. This review summarizes age related changes in the brain and the importance of oxidative/nitrosative stress 
and mitochondrial dysfunction in brain aging. The data and mechanisms of action of melatonin in relation to aging of the 
brain are reviewed as well.  
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INTRODUCTION: MELATONIN SYNTHESIS AND 
ITS ACTION´S MECHANISMS 
  Melatonin is an ancient and highly conserved in-
doleamine derived from tryptophan. It is present in bacteria, 
eukaryotes, plants and all phyla of muticellular animals.   
Because of its ancient origin, it is thought that melatonin 
posseses numerous functions acquired throughout evolution 
[59]. 
  The biosynthesis of melatonin requires four enzymatic 
steps. First, tryptophan hydroxylase catalyzes the conversion 
of tryptophan to 5-hydroxytryptophan, which is then decar-
boxylated by aromatic amino acid decarboxylase to produce 
serotonin. Therefore, the enzyme arylalkylamine N-acetyl- 
transferase (AANAT) converts serotonin to N-acetylserotonin, 
which is then O-methylated by the action of the hydroxyindole-
O-methyltransferase (HIOMT) to produce melatonin [47].   
In mammals, melatonin is synthesized by the pineal gland  
in a circadian manner and it is released into blood and   
into the cerebrospinal fluid (CSF). In the blood melatonin 
can concentrate up to 0.5 nM [47, 132]. 
  Blood melatonin concentrations exhibit higher values 
(10–15-fold increase) during the night than during the   
daytime. This circadian rhythm is present in all living   
organisms, from unicellular to multicellular organisms in-
cluding humans. In vertebrates, the rhythm is generated by a 
biological clock situated in the suprachiasmatic nucleus 
(SCN) of the hypothalamus, and synchronized to 24 h pri-
marily by the light–dark cycle acting via the SCN [79]. In 
humans, these rhythms are developed during the first months  
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of life and reach the greatest magnitude between the 4 and 
7th year of age. At puberty, there is a drop in melatonin con-
centrations, and thereafter plasma concentrations diminish 
gradually. After that, melatonin production in the pineal 
gland declines progressively with age [79]. As a consequence, 
in many elderly individuals the day–night differences in 
melatonin secretion are almost absent. Therefore, in old   
animals and elderly humans the levels of melatonin available 
to the organism are a small proportion of that of young   
individuals [133].  
  In addition to the melatonin produced by the pineal 
gland, melatonin is also generated in many tissues and   
organs of the body, and this extrapineal production of   
melatonin is much more greater than that produced by the 
pineal [152]. The expression of genes for the key enzymes 
for melatonin synthesis, AANAT and HIOMT has been 
found in many organs [146]. Interestingly, melatonin is con-
centrated by subcellular compartments including nucleus and 
mitochondria, the latter showing 100-200 times more mela-
tonin than cytosol [5, 95].  
  The multiple sources of melatonin are associated to   
different indoleamine levels in different tissues, cell types 
and subcellular compartments and presumably related to the  
specific actions of the indoleamine in these tissues. Some   
of these actions are especially remarkable for the potential 
benefits in the brain, especially during the physiological   
aging and in pathophysiological age-related disorders: 1) In 
contrast to numerous synthetic and natural drugs, melatonin 
is readily administrated orally and it is readily available   
to the brain [88], 2) numerous in vitro and in vivo studies 
have demonstrated the capacity of melatonin to counteract 
oxidative stress and oxidative damage [7, 134, 135, 136], 3) 
melatonin reduces chronic and acute inflammation in the 
brain [6], and 4) melatonin plays an important role in   
the mitochondrial homeostasis, especially in response to mi-
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MITOCHONDRIA, MELATONIN AND AGING 
BRAIN 
  The mammalian brain is a tissue with high energy   
demand and it possess highly active mitochondria metabolism 
with high oxygen utilization (20% of the total oxygen   
inspired). Consequently, reactive oxygen species (ROS)   
generation in the brain is intense. In addition, the brain is 
very susceptible to free radical damage because of its high 
concentrations of polyunsaturated fatty acids [48] and transi-
tion metals such as iron, which is involved in the generation 
of the hydroxyl radical [65] , moreover, the brain contains 
low concentrations of cytosolic antioxidants [40, 134].   
Remarkably, it has been shown that the cognitive functions, 
motor ability, exploratory capacity and neuromuscular   
coordination in mice are decreased upon aging in parallel 
with an increase of protein oxidation and a reduction in   
mitochondrial complex activities in the brain of these   
animals [49, 114]. 
  Several lines of evidences have shown the relation   
between aging, increased oxidative damage and mitochondrial 
dysfunction. Oxidative damage to mitochondria influences 
different structural and functional components of mitochondrial 
DNA (mtDNA), proteins and membrane lipids. Three factors 
make mtDNA particularly vulnerable to reactive species: 
mtDNA is located close to the mitochondrial inner mem-
brane, near the generation of ROS; mtDNA is not   
extensively condensed and protected by histones; mtDNA 
repair is limited [26], the expression of the entire mtDNA is 
essential for the maintenance of mitochondrial bioenergetic 
function, while only about 7% of the nuclear genome is   
expresses during cell differentiation [109]. 
  Age-related mtDNA deletions have been detected in   
humans in a wide variety of aged tissues including the   
brain, and the correlation of the rise in mtDNA deletions and 
mitochondrial respiratory chain malfunction during aging 
has been amply demonstrated [14, 29, 86, 162]. The global 
deletion levels rarely exceed 1% and, therefore, the contribu-
tion of mtDNA deletions to the aging process appear to be 
unlikely. However, the deletions levels in particular areas 
and cell types are still unknown. On the other hand, the 
mechanisms of mtDNA deletions during aging are still   
controversial but oxidative damage to DNA associated with 
single or double-stranded breaks has been proposed. This 
idea has been supported for several studies: the relative 
amount of mtDNA deletions correlates with the levels of 8-
hydroxy-2'-deoxyguanosine (8-OHdG) [62], and treatment of 
human skin fibroblasts with sub-lethal dose of oxidative sub-
stances and environmental insult inducers of ROS results in 
the formation and accumulation of the 4977 bp deletion in 
mtDNA [16, 41]. 
  mtDNA point mutations and duplications in tRNA,   
protein-coding genes and D-Loop have been also found   
to accumulate in some post-mitotic tissues during human 
aging [36, 108, 160]. However, it seems that the proportion 
of mutant mtDNAs is too low to cause a significant impact 
on mitochondrial function in aging tissues. On the other 
hand, the distribution of the mutant mtDNA in cells and   
tissues is still unknown and clarification of this matter   
could resolve important questions regarding the importance of 
mtDNA mutations in aging [99]. Additionally, mitochondria 
polymerase   (POLG) deficient mice accumulate high   
levels of mtDNA mutations and deletions resulting in a   
premature aging phenotype with COX deficient cells in the 
brain and heart but without an increase of ROS generation 
and oxidative damage [87, 156, 159]. Thus, these results 
support the idea of a direct involvement of mtDNA   
mutations in aging but cast doubt on the vicious cycle 
theories of aging and oxidative stress [93]. 
  Some explanations have been proposed, however, to   
account the lack of oxidative stress in POLG deficient mice: 
aging is the result of alterations in many pathways and, 
therefore, the aging phenotype in the mutator mice should 
not be compared to normal aging; alterations in POLG   
may be downstream from mechanisms that generate ROS; 
and extensive and equally distributed mtDNA mutations   
(in contrast to the mosaic distribution of mtDNA mutations 
observed in normal aging) could prevent the generation of 
ROS [93]. In contrast to POLG mutant mice, skin fibroblasts 
harboring mtDNA point mutations associated with aging 
show an alteration in the expression profile of antioxidant 
enzymes [161]. 
  In addition to the research related to mtDNA alterations, 
mitochondrial protein oxidation has been also reported in a 
variety of organisms during aging [99]. The proteins containing 
Fe-S clusters seem to be the most susceptible to oxidation 
[99]. Several reports have revealed that oxidation of   
aconitase, adenine nucleotide translocase and mitochondrial 
respiratory chain complexes may occur during aging and 
consequently the activities of these enzymes diminish with 
increasing age [9, 168, 169]. Oxidative injury is not limited 
to mtDNA or proteins but also to mitochondrial membranes. 
This may lead to a progressive lipid peroxidation (LPO)   
and cross linking damage, with simultaneous changes in   
the respiration rate, ATP synthesis, membrane fluidity and 
permeability, Ca
2+ homeostasis and apoptosis [3]. 
  Alterations in the expression and activities of the antioxi-
dant enzymes in response to the oxidative environment in the 
aging cells has been found in human blood [10, 33, 57] and 
muscle [102, 121], and in a variety of tissues from rats and 
mice, including skeletal muscles, brain and heart, which are 
tissues with high energy demand. Additional information 
about the physiological changes in mammalian aging has 
been uncovered by studies performed in the senescence-
accelerated mouse (SAM) [150]. SAM includes two strains, 
one prone to accelerated senescence (SAMP) and one resis-
tant to accelerated senescence (SAMR). SAMP8, a sub-strain 
of SAMP, shows relatively strain specific age-associated 
phenotypic pathologies such as a shortened life span   
and early manifestation of senescence (including loss of   
activity, alopecia, lack of hair glossiness, skin coarseness,   
periphthalmic lesions, increased lordokyphosis and systemic 
senile amyloidosis), similar to several geriatric disorders 
observed in humans [148, 150]. SAMP8 mice show a general 
hyperoxidative status manifested by increased mitochondrial 
electron leakage and ROS production, elevated LPO and 
protein carbonyl content, changes in the antioxidant enzymes 
activities and increase of GSSG:GSH ratio [23, 68, 92, 105, 
117, 149, 171]. The results are a loss in the mitochondrial 
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the organism, suggesting that the mechanism of senescence 
acceleration in SAMP8 mice is related to free radical damage 
[138,139]. SAMP8 mice also show an age-dependent   
increase in IFN- and TNF-, a reduction in IL-2 levels   
and an rise in nitric oxide (NO•) levels [140], suggesting   
the existence of an inflammatory process during aging.   
The increase of NO• levels is particularly relevant since   
this molecule reacts with (O2
._) in mitochondria yielding 
peroxynitrite anion [126], which irreversible impairs the   
mitochondrial respiratory chain and decreases the efficiency 
of oxidative phosphorylation, leading to energy depletion 
and cell death [20, 25]. 
  Numerous studies have shown that melatonin directly 
scavenges free radicals, stimulates other antioxidant systems 
of the cells and inhibits the expression of iNOS with the   
subsequent reduction in the levels of both ROS and RNS [3, 
6, 8]. In recent studies, Jou and colleagues [73, 74] demon-
strated that cybrids with 80% common deletion in mtDNA 
showed an increase in oxidative stress and an rise in suscep-
tibility to a secondary oxidative stress induced by H2O2 ex-
posure. Interestingly, melatonin reduced ROS generation in 
both conditions preventing ROS-mediated depolarization of 
mitochondrial membrane potential and subsequent opening 
of the mitochondrial permeability transition pore (MPTP) 
and cytochrome c release [74]. The protection provided by 
melatonin was superior to other antioxidants such us vitamin 
E and mitochondria targeted coenzyme Q (MitoQ) [74].  
  The effects of melatonin in counteracting oxidative   
damage and mitochondrial dysfunction have been also tested 
in the brain of mice with accelerated aging, SAMP8 [24]. 
Chronic melatonin administration in the drinking water   
for 9 months (10 mg/kg b.w.) completely prevented the   
mitochondrial impairment maintaining or even increasing 
ATP production. Likewise, melatonin prevented the rise in 
mitochondrial LPO and increased GPx and GRd activities 
normalizing the GSSG/GSH ratio [24]. Melatonin also   
counteracted the oxidative damage to the mitochondrial 
membranes of the brain during aging since it prevented rigidity 
in the mitochondrial membrane and preserved the content 
and structural integrity of cardiolipin molecules [54, 125]. 
Immune function in the brain is other important factor in 
aging. Nitrite levels accurately reflect the nitrosative stress 
status that is caused by inflammation. Importantly,   
age-dependent nitrosative status in brain mitochondria was 
prevented by melatonin administration [24]. The effect of 
melatonin in the reduction of nitrosative stress has been   
amply studied in animal models of sepsis. The administration 
of pharmacological doses of melatonin in rodents with sepsis 
induced by lipopolysacharide injection or cecal ligation and 
puncture (CLP) produced a decrease in the expression and 
activity of iNOS, and consequently nitrite levels, nitrosative/ 
oxidative stress and mitochondrial function were normalized 
[42, 43, 45, 96, 97]. Interestingly, the increase of iNOS   
expression was more pronounced in aged rats (18 m.o.) than 
young rats (3 m.o.), but melatonin was able to reduce the 
expression to the same levels in both groups [42, 44]. 
MITOCHONDRIA, MELATONIN AND NEURODE-
GENERATIVE DISORDERS 
 Aged-related disorders include neurodegenerative   
diseases of different etiologies that may share mitochondrial 
dysfunction, oxidative/nitrosative stress and apoptosis in 
particular brain areas as a final common pathway. Conse-
quently, neuronal loss may be associated to mitochondrial 
dysfunction in those disorders. Alzheimer disease (AD) is a 
predominantly sporadic late-onset disorder characterized by 
progressive dementia with a relatively long course. Progressive 
neuronal loss, particularly in the cortex and the hippocampus, 
is typically observed in the brain of Alzheimer patients. The 
two main histopathological features of AD are the accumulation 
of extracellular neuritic plaques, mainly represented by   
-amyloid (A), and of neurofibrillary tangles, mainly   
represented by the hyper-phosphorylated forms of the   
microtubule-associated protein tau [56]. Additionally, some 
evidence indicates that mitochondria are involved in the   
pathology of AD, including a reduction in brain energy   
metabolism shown by positron emission tomography [11], 
defects of mitochondrial metabolic enzymes [104, 144],   
mitochondrial respiratory chain complex deficiencies [19, 85] 
and an increase of mtDNA deletion level in the substantia 
nigra neurons [15]. On the contrary, a recent review found 
little evidence in support a role of mtDNA mutations in the 
development of AD [69].  
  It has been shown that -amyloid peptide generates ROS 
in a metal-catalyzed reaction, which induces neuronal   
cell death in a ROS-mediated process resulting in damage  
to neuronal membrane lipids, proteins and nucleic acids. 
This suggests that the use of antioxidants such as vitamin E, 
melatonin or estrogens may be beneficial in AD [90, 110].  
In AD patients, melatonin levels are reduced in blood   
and CSF and that reduction seems to go in parallel to the 
progression of AD neuropathology [165, 174]. Moreover, 
CSF melatonin levels are already decreased in pre-clinical 
AD individuals [165]. 
  The administration of melatonin has been tested in order 
to reduce the neurodegenerative manifestations in AD [123]. 
When neuroblastoma cells were incubated with A, more 
than 80% of the neurons died due to apoptosis, but the   
presence of melatonin reduced cellular death and DNA   
damage in a dose-related manner [124]. In human platelets, 
melatonin also protected against A-induced damage [21, 
122]. Recently, melatonin treatment has been tested in the 
APP + PS1 double transgenic (Tg) mouse, which is considered 
a mouse model with characteristics of the neuropathology   
of AD [119]. Melatonin administred in the drinking water 
(100 mg/L water) for four months protected AD mice from 
cognitive impairment in a variety of tasks of working   
memory, spatial reference learning/memory, and basic   
mnemonic function. Immunoreactive A deposition was 
significantly reduced in hippocampus (43%) and entorhinal 
cortex (37%) of melatonin-treated AD mice. The levels   
of tumor necrosis factor (TNF)-alpha were reduced in the 
hippocampus of AD mice treated with melatonin, as well as 
the cortical mRNA expression of SOD-1, GPx and catalase. 
Taken together, the results suggest that melatonin's cognitive 
benefits could involve its anti-A aggregation, anti-
inflammatory, and/or antioxidant properties [119]. In AD 
patients, melatonin stabilizes cognitive function over a 2–
3  year period [21, 22]. An additional retrospective study   
reported that individuals with mild cognitive impairment 
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significantly better cognitive performance in two widely 
utilized cognitive assessment tests [52]. 
  Parkinson disease (PD) is a mainly sporadic late-onset 
disorder characterized by bradykinesia, rigidity and tremor. 
PD is accompanied by the loss of about 60% of dopaminergic 
neurons of the substantia nigra pars compacta. Mitochondrial 
involvement in PD is suggested by deficiencies of complex I 
(C-I) in substantia nigra [142], with a parallel reduction   
in GSH levels, suggesting the existence of oxidative stress. 
In platelets of PD patients, C-I is also decreased and in   
some cases is accompanied by complex II (C-II), complex III 
(C-III) and complex IV (C-IV) deficiencies. 
  Mitochondrial involvement in the pathology of PD has been 
genetically supported by the finding of POLG mutations in 
early-onset Parkinsonism in different families [32, 98]. In 
some cases, the POLG mutations were accompanied by mtDNA 
deletions, ragged-red and cytochrome c oxidase-negative 
fibers and low activities of mitochondrial complexes containing 
mitochondrial DNA-encoded subunits [32, 98]. Additionally, 
analysis of single substantia nigra neurons from individuals 
with PD and age-mathed controls showed an age-related 
accumulation of high levels of mtDNA deletions [14]. On 
the contrary, a recent review of the evidence for primary 
mtDNA mutations in PD led to the conclusion that there is 
no convincing proof for a primary role of mtDNA mutations 
in this neurodegenerative disorder [69].  
  A series of nuclear genes (PARK2,  PARK7,  PINK1, 
SNCA, LRRK2 and HTRA2) are recognized to be associated 
with the familial form of PD and the proteins encoded by 
these genes interact directly or indirectly with mitochondria 
and seem to be involved in apoptosis [35]. Moreover, some 
environmental toxins seem to interact with the products of 
these genes, which provoke oxidative damage, mitochondrial 
dysfunction and cell death [2]. These environmental toxins 
influence PD, as shown by the C-I inhibitory effects of 1-
methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP), rotenone 
and paraquat. The C-I inhibition is prevented by free radical 
scavengers indicating oxidative damage to C-I. Moreover, 
MPTP also stimulates NMDA-dependent nNOS activity 
thereby increasing NO• production [155], and decreasing   
the content of mtDNA [111]. In mouse models of PD   
induced by MPTP melatonin administration normalized 
complex I activity and oxidative status in mitochondria from 
substantia nigra and striatum. 
  Looking for the targets of melatonin action, it was   
recently shown that this indole reduced the activity of the 
mitochondrial iNOS (i-mtNOS), thus decreasing mitochondrial 
NO• levels and preventing the respiratory inhibition   
produced by NO• at the level of complex IV [153]. Melatonin 
also protects against excitotoxicity by reducing the autoxidation 
of dopamine (DA) which occurs in PD [80]. These effects 
were demonstrated in MPTP-induced PD in mice [4, 120] 
and in PC12 cells incubated with 6-hydroxydopamine [106]. 
Melatonin also abrogated cell death induced by cysteamine 
pretreatment of the PC12 cells; cystamine treatment involves 
mitochondrial iron sequestration [50].  
  The age-associated accumulation of redox-active iron   
in subcortical astrocytes may facilitate the bioactivation   
of DA to neurotoxic free radical intermediates and thereby 
predispose the nervous system to PD and other neurode- 
generative diseases. In rats injected with kainic acid to   
produce excitotoxicity-induced apoptotic cell death,   
melatonin significantly attenuated apoptosis, an effect linked 
to the reduction in oxidative damage and an increased   
GSH content [27]. In a spontaneous, age-induced model of 
apoptosis using cerebellar granule cells, it was shown that 
melatonin and Ca
2+-channel blockers such as amlodipine, 
inhibited spontaneous apoptosis [103]. This antagonism   
between melatonin and Ca
2+-channels was also demonstrated 
in electrophysiological and binding experiments [46]. Striatal 
neurons growing in low density culture in serum-free   
medium and in the absence of glia die within 3 days by 
apoptosis. The presence of melatonin rescues striatal neurons 
from impending cell death, which has important conse-
quences in neurodegenerative diseases involving nigrostriatal 
pathway such as in PD [71].  
  Huntington’s disease (HD) is a neurodegenerative   
disorder characterized by ataxia, chorea and dementia. It is 
known to be caused by an alteration in a gene for nDNA 
encoding huntingtin, a widely expressed protein of unknown 
function but associated with inappropriate apoptosis. The 
pathology of HD involves mainly the GABA-containing 
neurons of the caudate nucleus and putamen [142]. Excito-
toxicity has been suggested to play an important role in this 
disease. This includes activation of NMDA-dependent   
neuronal nitric oxide synthase (nNOS) and NO• production. 
NO• and particularly peroxynitrite mediate oxidative damage. 
Increases in mtDNA copy number and multiple mtDNA   
depletions have been found in HD patients, which are   
especially common in the frontal and temporal lobes of the 
cerebral cortex, although its significance is unclear [67, 130]. 
These mtDNA alterations could be a consequence of the 
increase of the oxidative damage to DNA reflected by an 
elevation of the levels of 8-hydroxydeoxyguanosine [130]. 
There are also deficiencies in the activities of C-II, C-III and 
C-IV in caudate and in a lesser extend in putamen in HD. 
  Others mitochondrial abnormalities have been found   
in cells and animals models of HD, which include calcium 
dyshomeostasis and anomalous mitochondrial dynamics 
[130]. Melatonin treatment has been used in a rat model   
of Huntington disease induced by 3-nitropropionic acid,   
a mycotoxin that inhibits the mitochondrial succinate   
dehydrogenase or complex II [157]. The inhibition of complex 
II by 3-nitropropionic acid was accompanied by rises in LPO 
and protein carbonyl content, and a decrease in SOD activity 
in the brain cortex and striatum. Melatonin administered 
intraperitoneally (1 mg/kg b.w./day) for 8 days prevented the 
deleterious effects induced by the acid [157]. 
  Amyotrophic lateral sclerosis (ALS) is a late-onset   
sporadic disorder clinically characterized by  progressive 
muscle weakness, atrophy, spasticity widespread paralysis 
and premature death. The disease is caused by the degeneration 
and death of upper and lower motor neurons in the cortex, 
brainstem, and spinal cord [64]. About 5%–10% of patients 
have a familial form of ALS (FALS), and about 20% of 
these harbor mutations in the SOD1 gene that encodes the 
Cu,Zn-superoxide dismutase 1 (SOD1) [64]. Mouse models 
overexpressing mutant SOD1 also develop motor neuron 
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SOD1 activity, and some studies have proved that a portion 
of mutant SOD1 is localized in mitochondria, both in FALS 
patients and in the animal models. As a result, it has been 
hypothesized that mutant SOD1 may damage mitochondria 
by some misunderstood mechanism [64]. 
A recent investigation has used melatonin in cellular and 
mouse models of ALS, as well as 31 ALS patients [163]. 
First, NSC-34 cells, a widely used motoneuron-neuroblastoma 
fusion line, were exposed to 2 or 10  mM of glutamate   
for 3 days. A mortality of 29.2% and 52.1% of cells were 
detected, respectively; treatment with 50 mM melatonin   
recovered the survival by 17.2 % (2 mM glutamate) and   
8.5 % (10 mM glutamate). Melatonin reduced the elevated 
ROS production in this cellular model. Second, in   
the SOD1
G93A-transgenic mouse (an ALS mouse model), 
melatonin was administrated in the drinking water (0.5 
mg/ml water) at 28 days old, resulting in a delayed disease 
progression and extended survival; third, daily doses of 300 
mg melatonin were administrated in ALS patients as novel  
suppositories at bedtime. Melatonin treatment decreased   
the serum protein carbonyls compared with the elevated   
levels presented in the serum of  the matched untreated   
ALS patients [163]. 
NEURAL STEM CELLS IN AGING AND AGED-
RELATED DISORDERS: THE IMPORTANCE OF 
MITOCHONDRIA AND OXIDATIVE STRESS 
  Stem cells can be classified in three types: pluripotent 
embryonic stem cells (ESC) that have the potential to   
differentiate into any cell type in the organism; multipotent 
cells derived from adult tissue including umbilical cord 
blood and amniotic fluid, which can differentiate into a   
limited number of cells types of their own lineage, e.g., 
mesoderm; and precursor cells, which are adult stem cells 
committed to differentiation. In the brain, both neural   
stem cells and neural progenitor cells are responsible for 
neurogenesis. Neural stem cells produce additional stem 
cells as well as offspring that go on to differentiate into   
oligodendrocytes, other glial cells and neurons. Neural   
progenitor cells have a limited replicative potential that   
are committed to the neuronal lineage [175]. The vast   
majority of cells in the adult central nervous system (CNS) 
are generated during the embryonic and early postnatal   
period, but some proportion of neurogenesis is also occurs 
during adulthood. The functional significance of the adult 
neurogenesis is not fully understood but it has been shown  
to be involved in several brain function and pathologies   
[38, 175]. Neurogenesis in the adult brain from mammals   
is concentrated in the subventricular zone (SVZ) of the lat-
eral ventricule wall and the subgranular zone (SGZ) of the 
dentate gyrus of the hippocampus [175]. New cells generated 
from these regions migrate toward their final destinations, 
where they differentiate into mature cells and are integrated 
into the CNS [76, 175]. 
  Age-related changes have been observed in both SVZ 
and SGZ, which are associated with a decline of neurogenesis 
during aging [38, 175]. These changes may affect the   
different steps on neurogenesis: 1) proliferation of new cells; 
2) survival of newly born cells; 3) migration of these cells 
toward target areas; and 4) differentiation into mature   
functional cells. 
  Neural stem cell proliferation has been widely studied   
in rodents by use of cell proliferation markers such as 
bromo-deoxyuridine (BrdU) and tritiated thymidine [76, 
175]. Most results have shown that cell proliferation declines 
during aging in both SVZ and SGZ [76, 175]. However, the 
difference in the proliferation decline is not clear between 
middle age and senescence since some studies have reported 
significant changes in both ages groups [18, 129] but others 
did not [39, 128]. 
  On the contrary, the short-term survival pattern in   
the newborn cells seems to be unaffected by aging [38]. 
However, when some brain areas are damaged, the survivals 
of newborn cells show clear differences between young   
and old animals. In one study of stroke simulation, rats 
subjected to ischemia showed an induction of neural stem 
cell proliferation in the SGZ. One day after the ischemia 
induction young adults exhibited a 5.7 fold increase in BrdU 
labeled cells compared to a 10.6-fold increase in old adults. 
Remarkably, 65.5% of the labeled cells survived 28 days 
after ischemia in young adults, whereas in old adult brains 
only 15.3% remained [167]. 
  In other study, Zaman and Shetty [173] observed   
that when hippocampi was first damaged by the action   
of kianic acid, a specific agonist for kainite receptors with 
neuroexcitotoxic and epileptogenic properties, the survival of 
rat fetal hippocampal cells injected into the ventricles of rats 
was 30% in middle-aged and old brains compared with the 
72 % survival in young brains. Both studies suggested that 
changes in the environment of the brain areas during aging 
may be critical for the survival of new cells [167, 173]. Thus, 
the increases of glucocorticoids and the decreases of the 
levels of Insulin-like growth factor 1 (IGF-1) in aged brain 
have been associated to a decrease in neurogenesis [1, 91, 
115]. 
  Interestingly, oxidative stress, which is particularly 
increased in the rat hippocampus during aging [116], also 
may play an important role in neural and progenitor stem  
cell survival. It has been shown that curcumin, an antioxidant 
and anti-inflammatory agent, modulates the proliferation of 
embryonic neural progenitor cells with a biphasic effect in 
cultured cells. In mouse brain, curcumin administration   
resulted in a significant rise in the number of newly-generated 
cells in the SGZ of hippocampus [82]. Oxidative stress   
disrupts the differentiation of oligodendrocyte precursors   
and neural progenitor cells into mature oligodendrocyte and 
neurons [51, 143]. On the contrary, the increase of the anti-
oxidant capacity protects neural progenitor cells in vitro and 
potentiates the formation of cellular networks that   
provide neuroprotection in vivo [100, 143]. 
  An increase in newly generated neural cells in adult brain 
and an increase in the resistance of neurons to dysfunction 
and apoptosis have been detected in rodents undergoing   
dietary restriction. Both oxidative stress and dietary   
restriction are interlinked and related to mitochondrial   
function. However, few studies have focused in the role   
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of neural stem cells, and most of them are related with   
the mitochondrial apoptotic pathway induced by some toxic 
agent [77, 78,151, 154]. 
  Interestingly, some studies in embryonic stem cells 
(ESC) have focused on the activity of mitochondrial genome 
and of these data could be extrapolated to neural stem cells. 
Transmitochondrial embryonic stem cells harboring patho-
genic mtDNA mutations have shown to be compromised in 
neuronal differentiation when the mitochondrial respiratory 
chain function is severely affected [84]. Thus, some authors 
have hypothesized that stem cell competence may be verified 
using functional mitochondrial characteristics [94]. Differen-
tiation of mouse and human embryonic stem cells (ESC) 
results in changes in mitochondrial structure, morphology 
and pattern of cytoplasmic localization. Mitochondria   
in stem cells tend to localize perinuclearly [94]. Moreover, 
ESC have relatively few mitochondria with poorly developed 
cristae [28, 118], and restricted oxidative capacity. As cells 
are allowed to differentiate, the number of mtDNA copies 
increase and these differentiated cells contain elevated   
numbers of mitochondria with distinct cristae, dense   
matrices and high membrane potentials. These features   
suggest the initiation of metabolic activity through oxidative 
phosphorylation (OXPHOS) [145]. Because ESC display 
low oxygen consumption and thus, poor OXPHOS, an   
elevation in ATP content per cell may therefore reflect a   
loss of stemness and the subsequent onset of differentiation 
[28, 94]. Therefore, preservation of immature mitochondria 
with a perinuclear arrangement, reduced expression of   
OXPHOS enzymes and low metabolic activity in ESC has 
led to the suggestion that these mitochondrial properties 
might be important for the maintenance of pluripotency and 
should be considered as another ESC marker. Departures 
from this profile indicate that cells are differentiating or   
perhaps becoming senescent. 
  The increase in mitochondrial mass is accompanied by 
elevated ATP production and, thus, by a greater generation 
of ROS. Undoubtedly, the intracellular levels of ROS are 
higher in differentiated than in undifferentiated ESC, due to 
the increase in OXPHOS metabolism in the former [141]. An 
increase in ROS levels might have a role in cell signaling 
and regulation of proliferation and differentiation. Exposure 
to low levels of ROS has been reported to enhance ESC dif-
ferentiation whereas continuous exposure to high levels of 
ROS results in inhibition of differentiation [141]. Therefore, 
differentiating cells probably activate effective antioxidant 
systems, including catalase, GPx and others. In summary, 
successful differentiation of embryonic cells in vivo or   
ESC in vitro involves initiation of mtDNA transcription and 
replication, an increase in the number of mitochondria,   
and regulation of the enzymes required for aerobic   
metabolism in order to fulfill the elevated ATP requirements 
of fully differentiated cells. 
  The migration and differentiation of neural and progenitor 
stem cells may also be affected with aging. It has been   
reported that the capacity of the newly born cells to migrate 
from SGZ to the granule cell layer is decreased with aging 
[63]. Several studies have also shown different grades   
of reduction in the differentiation of neural stem cells into 
neurons [38] and the reduction in the dendritic maturation 
during aging [38, 129].  
  In addition of the alterations in neurogenesis during 
physiological aging, some insults can also dramatically af-
fect this process. Neurodegenerative diseases are character-
ized by loss of neurons and newly-generated neurons should 
appear in the damaged area to repair this injur. However, 
recent studies have documented alterations in neurogenesis 
in neurodegenerative diseases. Cell proliferation is signifi-
cantly repressed in SVZ of PD patients and animals models 
of PD, resulting in a decrease in the numbers of neural stem 
cells and neuroblasts. Importantly, this reduction is more 
significant in PD patients with cognitive impairments than in 
those without [66]. AD is characterized by the accumulation 
of A that suppresses the proliferation of neural stem and 
progenitor cells and the neuronal differentiation in cell   
culture [60]. Mouse models of AD with accumulation of A 
and mice given A intravenously show a defect in neuronal 
production, survival and differentiation in the SGZ, as well 
as migration of neuroblasts [37, 61, 164]. Another proof   
of the involvement of neural stem cell in the pathology of 
AD is the fact that long term administration of cholinesterase 
inhibitors, which improve cognitive function in AD patients, 
promotes the survival of newly-generated neurons and   
increases neurogenesis in adult mice [75]. The pathophysiology 
of HD includes atrophy of the caudate nucleus and putamen, 
which are adjacent to the SVZ. Related to that, Curtis and 
colleagues [30, 31] observed an enhanced thickness of the 
SVZ together with an increase of cell proliferation in the 
brain of HD patients. Subsequently, Batista and colleagues 
[13] reported that the ability of neural stem cells dissociated 
from the SVZ of the R6/2 mice, a mouse model of HD, to 
self-renew increases in parallel with the progression of the 
disease. Likewise, they observed the presence of migrating 
neuroblasts and newly-generated neurons in the striatum   
of these mice. However, the migration of neuroblasts toward 
the olfactory bulb was significantly suppressed [13].   
Contrary to the SVZ, cell proliferation and neurogenesis of 
the SGZ are decreased in the mouse models of HD [55, 89], 
while the relation of these findings with the neuropathology 
of DH has not been clarified. 
  Independently of the involvement of neurogenesis in the 
pathology of neurodegenerative diseases, stem cell research 
focused in the cell replacement therapy is a promising treat-
ment for neurodegenerative disorders. Different strategies 
are currently being examined for the treatment of neurode-
generative disorders using neural stem cells, including   
approaches involving transplantation of exogenous cells or 
promoting proliferation of endogenous cells. In both cases it 
is believed that the increase in neural stem cells in the brain 
attenuates anatomic and functional deficits associated with 
diseases of the CNS via cell replacement, release of specific 
neurotransmitters and production of neurotrophic factors that 
protect injured neurons and promote neuronal growth. 
  In mouse models of HD, the administration of basic 
fibroblast growth factor (bFGF) increased the SVZ cell 
proliferation and increased migration of neuroblasts to the 
striatum and the regeneration of the striatal projection 
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dysfunction and the increase of the life-span of these mice. 
The rise of hippocampal neurogenesis by the enrichment   
of the mouse environment also delayed the progression of 
HD symptoms in the mouse model [158]. Recently, mouse 
neural stem cells were transplanted intraventricularly into 
R6/2 HD mouse model combined with dietary trehalose, 
which reduces cellular aggregate formation. The combined 
treatment resulted in an improvement of motor function, 
reduction in aggregate formation and increase of the   
life-span of the animals [170]. However, the information 
related to the migration and the survival of the grafted neural 
stem cells was not provided in this study [83]. Previously, it 
was shown that fetal cell transplantation ameliorated 
neuronal dysfunction and improved motor function in both, 
the HD mouse model and HD patients [12, 113].  
  Stem cell transplantation has been examined in animal 
models of ALS. Transplantation of neural stem cells isolated 
from fetal spinal cord or neurons generated from the NT2 
human teratrocarcinoma cell line in the spinal cord of ALS 
mice were effective in the functional improvement and in   
the delay of the progression of the disease [53, 166]. The 
transgenic SOD
G93A mouse model of ALS was transplanted 
with human neural stem cells overexpressing vascular 
endothelial growth factor (VEGF) resulting in a functional 
improvement and extended survival. The immunohisto- 
chemical analysis demonstrated that the transplanted neural 
stem cells migrated into anterior horn of the spinal cord and 
differentiated into motoneurons [70]. Thus, a clinical trial of 
mesenquimal stem cell transplantation in ALS patients has 
recently finished phase I and is currently underway on phase 
II [107]. 
  Recently, the effect of neural stem cell transplantation 
has been evaluated in mouse model of AD (3xTg-AD) which 
express pathogenic forms of amyloid precursor protein, pre-
senilin, and tau [17]. The results showed that hippocampal 
neural stem cell transplantation rescues the spatial learning 
and memory deficits in aged 3xTg-AD mice. However, these 
improvements were not associated with an alteration of Aß 
or tau pathology. Interestingly, the mechanism underlying 
the improved cognition involves an augmentation of   
hippocampal synaptic density, mediated by brain-derived 
neurotrophic factor (BDNF) [17]. To further confirm this 
result, aged 3xTg-AD mice were treated with recombinant 
BDNF, which mimicked the beneficial effects of neural stem 
cell transplantation. On the contrary, depletion of neural 
stem cell-derived BDNF failed to improve cognition or   
restore hippocampal synaptic density [17]. 
  Transplantation of human fetal ventral mesencephalic 
cells into the striatum of PD patients has been carried out 
since early 1990s in patients with advanced disease [83]. 
However, the evidence of poor survival of the transplanted 
cells in the brain together with the difficulties to obtain 
enough fetal tissue for transplantation have led to a   
redesigned stem cell therapeutical strategy in PD [58, 83]. 
Thus, dopaminergic neurons have been generated from   
embryonic stem cells, mesenchymal stem cells and neural 
stem cells following different experimental protocols [83]. 
Dopaminergic neurons generated from monkey embryonic 
stem cells and human neural stem cells have been trans-
planted into striatum of monkeys with PD induced by MPTP. 
The results showed a behavioral improvement of the PD 
monkeys [131, 147]. Transplantation of immortalized neural 
stem cells into the striatum of a rat model of PD also induced 
functional improvement [172]. Other strategies include the 
transplantation of neural stem cells transfected with specific 
genes such as tyrosine hydroxylase (TH) and GTP cyclohy-
drolase I (GTPCH1) [83]. 
  The use of stem cells for therapeutical purposes is a 
promising strategy but several issues must be clarified before 
of general use in clinical medicine. The concerns include: 1) 
it must be verified which type of stem cell is most suitable 
for each purpose; 2) stem cells that escape differentiation and 
selection processes might expand and produce tumor in the 
graft site following transplantation; 3) highly purified popu-
lations of neural cell types derived from embryonic or neural 
stem cells may contain other neuronal or glial cells types that 
could generated unpredictable interactions among grafted 
cells or host cells; and 4) earliest studies have demonstrated 
that the long-term survival and phenotypic stability of stem 
cell-derived neurons or glial cells in the graft following 
transplantation are unsuccessful [83]. Hence, it is necessary 
to establish which factors are involved in the poor survival 
and stability of the transplanted cell. Among them, the highly 
toxic oxidative and nitrosative environment in the aged brain 
and its interaction with mitochondrial function should be 
taken into account. 
NEURAL STEM CELLS AND MELATONIN 
  Whereas a role of mitochondria in stem cell proliferation 
and/or differentiation begins to have experimental support, 
the role of melatonin remains unclear. One can presume that, 
in view of the specific and significant effects of melatonin on 
mitochondrial physiology, the indoleamine may also affect 
mitochondrial physiology in stem cells. It was recently   
reported that melatonin modulates the proliferative and   
differentiative ability of the neural stem cells from fetal 
mouse brain in a concentration and exposure-timing dependent 
manner [112]. When pharmacological concentrations of 
melatonin (1-100 M) were applied during the proliferation 
period, the proliferation was diminished. Interesting, neural 
differentiation of these cells increased without affecting   
astroglial differentiation. Other data point towards a net   
hippocampal neurogenesis in adult mice by melatonin [127]. 
Interestingly, it was shown that pinealectomy causes loss of 
pyramidal neurons in rat CA1/3 hippocampal layers, an ef-
fect reversed by melatonin administration [34]. Melatonin 
also promotes neurogenesis and motor recovery after mild 
focal ischemia or cranial irradiation in mice [81, 101]. New 
experimental data suggest that melatonin induces neurogenesis 
in dentate gyrus of adult pinealectomized rats [137]. The 
effects of melatonin on neural proliferation and differentiation 
might be partly a result of melatonin´s activity in mitochondria. 
Clearly, additional studies are required to uncover the   
underlying actions of melatonin on neural stem cells. 
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